Synapse is the project manager for the ROADMAP project (Real world Outcomes across the Alzheimer’s Disease (AD) spectrum for better care: Multi-modal data Access Platform), kicked-off on November 16-17, 2016 in Barcelona, which will deliver a series of scalable, transferable data integration methods and tools for patient outcomes, developed and tested through pilot projects, which will provide the foundation for a Europe-wide Real World Evidence (RWE) platform on AD.

Successfully delivering therapies to people with AD will also depend on building a sustainable global payer strategy to address challenges around drug access to markets. This will be dependent on the integration of RWE in health care systems to support approval as well as HTA/payer evidence. The development of a sustainable global payers strategy is one of ROADMAP’s objectives.

As the result of an ageing population, rising costs and more specialised treatments, Europe is now facing an acute healthcare challenge. In no area is this more apparent than in AD and dementia. The European Union, with the world’s most diverse and sophisticated health care systems, is uniquely placed to develop and exploit technologies to support RWE; addressing operational issues of data access, integration and security, alongside hypothesis testing, ELSI, health economic and budget impact, at a level of detail and complexity not possible elsewhere.

ROADMAP will identify RWE to better inform regulators on matters of efficacy and safety, providers on cost effectiveness, industry on pricing and manufacturing and scientists on mechanisms and pathways, to accelerate decision-making on re-purposing current treatments and developing new treatments.

ROADMAP brings together world-leading experts from 22 partner organisations to apply cutting-edge technology to a body of data of unprecedented depth and breadth, drawn from 6 EU Member States (Denmark, France, Netherlands, Spain, Sweden, UK), involving 75 national databases and clinical registries, more than 40 cohorts, several studies and 5 dementia-relevant trials, providing a unique opportunity for RWE in general, as well as in the dementia context.

The 2-year project is led by Novartis and coordinated by the University of Oxford. Synapse leads the Project Management work package and is involved in the design and implementation of the communication and patient/healthcare provider engagement strategy within WP7.

ROADMAP is mainly sponsored by the European Union’s Horizon 2020 research and innovation programme and the European pharmaceutical industry (via EFPIA) under the auspices of the Innovative Medicines Initiative 2 Joint Undertaking (www.imi.europa.eu).

For more information, check out http://www.roadmap-alzheimer.org/.